Figure 4. The therapeutic effect of nanodisc vaccination in TC-1 head and neck cancer model.

To establish a head and neck model, C57BL/6 mice were inoculated with 50,000 TC1-luc cells in the inner lip on day 0. On days 6 and 12, animals were vaccinated with 20 μg E7 peptide and 10 μg CpG formulated as a soluble vaccine or sHDL vaccine. The route of vaccination was either s.c. at the tail base or intranasal (i.n.) vaccination as indicated. A) Tumor burden was monitored over time using in vivo whole animal imaging (IVIS). B) Animal survival was measured over 60 days. C-F) Three days after the second vaccination, the frequency of E7-specific CD8⍺+ T cells was measured among C-D) PBMCs or E-F) tumor tissues by the tetramer assay. Shown are C, E) the representative flow cytometry scatter plots and D, F) the average values of E7-tetramer+ CD8⍺+ T-cells. Data are presented as mean ± s.e.m. from a representative experiment from 2 independent experiments (n = 5). *p < 0.05, ****p < 0.0001 analyzed by (D, F) one-way ANOVA with Tukey’s HSD multiple comparison post hoc test or by (B) log-rank (Mantel−Cox) test.